Novo Nordisk outlines strategy amid rising pressure

Novo Nordisk has scheduled a Capital Markets Day in London on 21 September 2026. The event will be led by CEO Mike Doustdar and CFO Karsten Munk Knudsen, who plan to present an updated strategy and mid‑term financial targets to investors.

The meeting comes at a time when the company’s strategic direction and pipeline productivity are closely watched by the market. Management is expected to use the event to frame how recent business development moves feed into Novo Nordisk’s longer‑term growth plans.

Investor pressure on Novo Nordisk has been heightened by intensifying competition in the GLP‑1 and obesity market. Rival offerings in these therapeutic areas are challenging established products and sharpening questions about the durability of current revenue drivers.

Recent pipeline setbacks have added to these concerns, including halted cardiovascular trials that have increased scrutiny of the company’s research portfolio. These factors have fuelled calls for faster dealmaking and the development of new drug programmes beyond Novo Nordisk’s existing franchises.

As part of its response, Novo Nordisk has announced a licensing and discovery agreement with Orbis Medicines. The collaboration is structured to be worth up to $1.4 billion in upfront, development and commercial milestone payments, in addition to royalties.

The partnership focuses on developing oral macrocycle therapies targeting cardiometabolic diseases. By targeting cardiometabolic conditions with an oral approach, the deal is intended to broaden Novo Nordisk’s pipeline beyond its current injectable‑based portfolio in related areas.

The size and scope of the Orbis agreement underscore Novo Nordisk’s willingness to commit significant resources to external innovation. The structure of potential milestone and royalty payments reflects a long‑term commitment to advancing the resulting drug candidates through multiple stages of development and commercialization.

Novo Nordisk has also disclosed a collaboration with Anthropic to integrate advanced AI tools into its research operations. The company plans to apply Anthropic’s AI, including Claude Science, to key drug discovery workflows.

The goal of the collaboration is to accelerate R&D productivity by improving how novel targets and compounds are identified and optimized. Embedding AI into discovery processes is expected to support faster and more efficient decision‑making across early‑stage research.

Together with the Orbis Medicines agreement, the AI initiative with Anthropic forms a central part of Novo Nordisk’s current response to competitive and pipeline pressures. These moves provide concrete examples of how the company is seeking to diversify and strengthen its drug development pipeline ahead of the September 2026 Capital Markets Day.